Name
NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.
Date & Time
Friday, December 13, 2024
Speakers
Virtual Session Link
Total Minutes
11:41
OnDemand Video URL